From genotype to functional phenotype: Unraveling the metabolomic features of colorectal cancer

Genes

Volumn 5, Issue 3, 2014, Pages 536-560

  Bathe, Oliver F ^a   Farshidfar, Farshad ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Colorectal cancer; Functional genomics; Metabolomics

Indexed keywords

EID: 84905588913     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes5030536     Document Type: Review

References (125)

1. Miranda, E.; Destro, A.; Malesci, A.; Balladore, E.; Bianchi, P.; Baryshnikova, E.; Franchi, G.; Morenghi, E.; Laghi, L.; Gennari, L. et al. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br. J. Cancer 2006, 95, 1101-1107.
2. Oliveira, C.; Velho, S.; Moutinho, C.; Ferreira, A.; Preto, A.; Domingo, E.; Capelinha, A.F.; Duval, A.; Hamelin, R.; Machado, J.C. et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007, 26, 158-163.
3. Gunther, K.; Leier, J.; Henning, G.; Dimmler, A.; Weissbach, R.; Hohenberger, W.; Forster, R. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int. J. Cancer 2005, 116, 726-733.
4. Artinyan, A.; Essani, R.; Lake, J.; Kaiser, A.M.; Vukasin, P.; Danenberg, P.; Danenberg, K.; Haile, R.; Beart, R.W., Jr. Molecular predictors of lymph node metastasis in colon cancer: Increased risk with decreased thymidylate synthase expression. J. Gastrointest. Surg. 2005, 9, 1216-1221.
5. Lin, Y.M.; Furukawa, Y.; Tsunoda, T.; Yue, C.T.; Yang, K.C.; Nakamura, Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21, 4120-4128.
6. Arango, D.; Wilson, A.J.; Shi, Q.; Corner, G.A.; Aranes, M.J.; Nicholas, C.; Lesser, M.; Mariadason, J.M.; Augenlicht, L.H. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 2004, 91, 1931-1946.
7. Mariadason, J.M.; Arango, D.; Shi, Q.; Wilson, A.J.; Corner, G.A.; Nicholas, C.; Aranes, M.J.; Lesser, M.; Schwartz, E.L.; Augenlicht, L.H. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003, 63, 8791-8812.
8. Li, M.; Lin, Y.M.; Hasegawa, S.; Shimokawa, T.; Murata, K.; Kameyama, M.; Ishikawa, O.; Katagiri, T.; Tsunoda, T.; Nakamura, Y. et al. Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int. J. Oncol. 2004, 24, 305-312.
9. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330-337.
10. Ogino, S.; Goel, A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 2008, 10, 13-27.
11. Jass, J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50, 113-130.
12. Ogino, S.; Cantor, M.; Kawasaki, T.; Brahmandam, M.; Kirkner, G.J.; Weisenberger, D.J.; Campan, M.; Laird, P.W.; Loda, M.; Fuchs, C.S. Cpg island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006, 55, 1000-1006.
13. Samowitz, W.S.; Albertsen, H.; Herrick, J.; Levin, T.R.; Sweeney, C.; Murtaugh, M.A.; Wolff, R.K.; Slattery, M.L. Evaluation of a large, population-based sample supports a cpg island methylator phenotype in colon cancer. Gastroenterology 2005, 129, 837-845.
14. Weisenberger, D.J.; Siegmund, K.D.; Campan, M.; Young, J.; Long, T.I.; Faasse, M.A.; Kang, G.H.; Widschwendter, M.; Weener, D.; Buchanan, D. et al. Cpg island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with braf mutation in colorectal cancer. Nat. Genet. 2006, 38, 787-793.
15. Ogino, S.; Odze, R.D.; Kawasaki, T.; Brahmandam, M.; Kirkner, G.J.; Laird, P.W.; Loda, M.; Fuchs, C.S. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am. J. Surg. Pathol. 2006, 30, 1175-1183.
16. Soreide, K.; Janssen, E.A.M.; Soiland, H.; Korner, H.; Baak, J.P.A. Microsatellite instability in colorectal cancer. Br. J. Surg. 2006, 93, 395-406.
17. Grady, W.M.; Carethers, J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135, 1079-1099.
18. Walther, A.; Houlston, R.; Tomlinson, I. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut 2008, 57, 941-950.
19. Popat, S.; Hubner, R.; Houlston, R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23, 609-618.
20. Guastadisegni, C.; Colafranceschi, M.; Ottini, L.; Dogliotti, E. Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. Eur. J. Cancer 2010, 46, 2788-2798.
21. Laghi, L.; Malesci, A. Microsatellite instability and therapeutic consequences in colorectal cancer. Dig. Dis. 2012, 30, 304-309.
22. Ward, R.L.; Cheong, K.; Ku, S.L.; Meagher, A.; O'Connor, T.; Hawkins, N.J. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol. 2003, 21, 3729-3736.
23. Ogino, S.; Meyerhardt, J.A.; Kawasaki, T.; Clark, J.W.; Ryan, D.P.; Kulke, M.H.; Enzinger, P.C.; Wolpin, B.M.; Loda, M.; Fuchs, C.S. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007, 450, 529-537.
24. Watanabe, T.; Wu, T.T.; Catalano, P.J.; Ueki, T.; Satriano, R.; Haller, D.G.; Benson, A.B., 3rd; Hamilton, S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2001, 344, 1196-1206.
25. Jung, B.; Smith, E.J.; Doctolero, R.T.; Gervaz, P.; Alonso, J.C.; Miyai, K.; Keku, T.; Sandler, R.S.; Carethers, J.M. Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int. J. Cancer 2006, 118, 2509-2513.
26. Ribic, C.M.; Sargent, D.J.; Moore, M.J.; Thibodeau, S.N.; French, A.J.; Goldberg, R.M.; Hamilton, S.R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L.E. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349, 247-257.
27. Lao, V.V.; Grady, W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 686-700.
28. Matsui, M.; Chu, Y.; Zhang, H.; Gagnon, K.T.; Shaikh, S.; Kuchimanchi, S.; Manoharan, M.; Corey, D.R.; Janowski, B.A. Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res. 2013, 41, 10086-10109.
29. Svoboda, M.; Slyskova, J.; Schneiderova, M.; Makovicky, P.; Bielik, L.; Levy, M.; Lipska, L.; Hemmelova, B.; Kala, Z.; Protivankova, M. et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 2014, 35, 1510-1515.
30. Qi, P.; Xu, M.D.; Ni, S.J.; Shen, X.H.; Wei, P.; Huang, D.; Tan, C.; Sheng, W.Q.; Zhou, X.Y.; Du, X. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol. Carcinog. 2014, doi:10.1002/mc.22137.
31. Chen, T.; Yao, L.Q.; Shi, Q.; Ren, Z.; Ye, L.C.; Xu, J.M.; Zhou, P.H.; Zhong, Y.S. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1alpha (FIH-1). Cancer Biol. Ther. 2014, 15, 516-523.
32. Pichler, M.; Ress, A.L.; Winter, E.; Stiegelbauer, V.; Karbiener, M.; Schwarzenbacher, D.; Scheideler, M.; Ivan, C.; Jahn, S.W.; Kiesslich, T. et al. MIR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br. J. Cancer 2014, 110, 1614-1621.
33. Cappuzzo, F.; Sacconi, A.; Landi, L.; Ludovini, V.; Biagioni, F.; D'Incecco, A.; Capodanno, A.; Salvini, J.; Corgna, E.; Cupini, S. et al. Microrna signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Clin. Colorectal Cancer 2014, 13, 37-45.
34. Nosho, K.; Igarashi, H.; Nojima, M.; Ito, M.; Maruyama, R.; Yoshii, S.; Naito, T.; Sukawa, Y.; Mikami, M.; Sumioka, W. et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014, 35, 776-783.
35. Pizzini, S.; Bisognin, A.; Mandruzzato, S.; Biasiolo, M.; Facciolli, A.; Perilli, L.; Rossi, E.; Esposito, G.; Rugge, M.; Pilati, P. et al. Impact of micrornas on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 2013, 14, doi:10.1186/1471-2164-14-589.
36. Poliseno, L.; Salmena, L.; Zhang, J.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function of gene and pseudogene mrnas regulates tumour biology. Nature 2010, 465, 1033-1038.
37. Tay, Y.; Kats, L.; Salmena, L.; Weiss, D.; Tan, S.M.; Ala, U.; Karreth, F.; Poliseno, L.; Provero, P.; di Cunto, F. et al. Coding-independent regulation of the tumor suppressor pten by competing endogenous mrnas. Cell 2011, 147, 344-357.
38. Matassa, D.S.; Amoroso, M.R.; Agliarulo, I.; Maddalena, F.; Sisinni, L.; Paladino, S.; Romano, S.; Romano, M.F.; Sagar, V.; Loreni, F. et al. Translational control in the stress adaptive response of cancer cells: A novel role for the heat shock protein trap1. Cell Death Dis. 2013, 4, e851.
39. Dixon, D.A. Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr. Pharm. Des. 2004, 10, 635-646.
40. Pedersen, J.W.; Blixt, O.; Bennett, E.P.; Tarp, M.A.; Dar, I.; Mandel, U.; Poulsen, S.S.; Pedersen, A.E.; Rasmussen, S.; Jess, P. et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 2011, 128, 1860-1871.
41. Nakagawa, H.; Chadwick, R.B.; Peltomaki, P.; Plass, C.; Nakamura, Y.; de la Chapelle, A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl. Acad. Sci. USA 2001, 98, 591-596.
42. Levine, A.J.; Ihenacho, U.; Lee, W.; Figueiredo, J.C.; Vandenberg, D.J.; Edlund, C.K.; Davis, B.D.; Stern, M.C.; Haile, R.W. Genetic variation in insulin pathway genes and distal colorectal adenoma risk. Int. J. Colorectal Dis. 2012, 27, 1587-1595.
43. Guo, S.T.; Jiang, C.C.; Wang, G.P.; Li, Y.P.; Wang, C.Y.; Guo, X.Y.; Yang, R.H.; Feng, Y.; Wang, F.H.; Tseng, H.Y. et al. Microrna-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013, 32, 1910-1920.
44. Janku, F. Tumor heterogeneity in the clinic: Is it a real problem? Ther. Adv. Med. Oncol. 2014, 6, 43-51.
45. Mittal, D.; Gubin, M.M.; Schreiber, R.D.; Smyth, M.J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27C, 16-25.
46. + memory T cell engraftment. BMC Cancer 2003, 3, doi:10.1186/1471-2407-3-21.
47. Schwitalla, S. Tumor cell plasticity: The challenge to catch a moving target. J. Gastroenterol. 2014, 49, 618-627.
48. Navin, N.E. Tumor evolution in response to chemotherapy: Phenotype versus genotype. Cell Rep. 2014, 6, 417-419.
49. Wu, D.; Wu, P.; Huang, Q.; Liu, Y.; Ye, J.; Huang, J. Interleukin-17: A promoter in colorectal cancer progression. Clin. Dev. Immunol. 2013, doi:10.1155/2013/436307.
50. Grivennikov, S.I.; Wang, K.; Mucida, D.; Stewart, C.A.; Schnabl, B.; Jauch, D.; Taniguchi, K.; Yu, G.Y.; Osterreicher, C.H.; Hung, K.E. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491, 254-258.
51. Pozza, A.; Scarpa, M.; Ruffolo, C.; Polese, L.; Erroi, F.; Bridda, A.; Norberto, L.; Frego, M. Colonic carcinogenesis in ibd: Molecular events. Ann. Ital. Chir. 2011, 82, 19-28.
52. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
53. Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269-270.
54. Lee, H.S.; Kim, H.O.; Hong, Y.S.; Kim, T.W.; Kim, J.C.; Yu, C.S.; Kim, J.S. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. J. Nucl. Med. 2014, 55, 582-589.
55. Miles, K.A.; Ganeshan, B.; Rodriguez-Justo, M.; Goh, V.J.; Ziauddin, Z.; Engledow, A.; Meagher, M.; Endozo, R.; Taylor, S.A.; Halligan, S. et al. Multifunctional imaging signature for V-Ki-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J. Nucl. Med. 2014, 55, 386-391.
56. Babbar, M.; Sheikh, M.S. Metabolic stress and disorders related to alterations in mitochondrial fission or fusion. Mol. Cell. Pharmacol. 2013, 5, 109-133.
57. Grills, C.; Jithesh, P.V.; Blayney, J.; Zhang, S.D.; Fennell, D.A. Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One 2011, 6, e14635.
58. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269-1274.
59. Ino, K.; Yamamoto, E.; Shibata, K.; Kajiyama, H.; Yoshida, N.; Terauchi, M.; Nawa, A.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin. Cancer Res. 2008, 14, 2310-2317.
60. Sucher, R.; Kurz, K.; Weiss, G.; Margreiter, R.; Fuchs, D.; Brandacher, G. IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int. J. Tryptophan Res. 2010, 3, 113-120.
61. Cai, F.; Dupertuis, Y.M.; Pichard, C. Role of polyunsaturated fatty acids and lipid peroxidation on colorectal cancer risk and treatments. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 99-106.
62. McMillan, D.C.; Crozier, J.E.; Canna, K.; Angerson, W.J.; McArdle, C.S. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int. J. Colorectal Dis. 2007, 22, 881-886.
63. Crozier, J.E.; McKee, R.F.; McArdle, C.S.; Angerson, W.J.; Anderson, J.H.; Horgan, P.G.; McMillan, D.C. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer. Br. J. Surg. 2007, 94, 1028-1032.
64. Yun, J.; Rago, C.; Cheong, I.; Pagliarini, R.; Angenendt, P.; Rajagopalan, H.; Schmidt, K.; Willson, J.K.; Markowitz, S.; Zhou, S. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325, 1555-1559.
65. Weinberg, F.; Hamanaka, R.; Wheaton, W.W.; Weinberg, S.; Joseph, J.; Lopez, M.; Kalyanaraman, B.; Mutlu, G.M.; Budinger, G.R.; Chandel, N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107, 8788-8793.
66. Chatr-aryamontri, A.; Breitkreutz, B.-J.; Heinicke, S.; Boucher, L.; Winter, A.; Stark, C.; Nixon, J.; Ramage, L.; Kolas, N.; O'Donnell, L. et al. The biogrid interaction database: 2013 Update. Nucl. Acids Res. 2013, 41, D816-D823.
67. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucl. Acids Res. 2000, 28, 235-242.
68. Magrane, M.; Consortium, U. Uniprot knowledgebase: A hub of integrated protein data. Database 2011, 2011, doi:10.1093/database/bar009.
69. Furlan, D.; Sahnane, N.; Carnevali, I.; Cerutti, R.; Uccella, S.; Bertolini, V.; Chiaravalli, A.M.; Capella, C. Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. Surg. Oncol. 2007, 16, S25-S27.
70. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
71. Levine, A.J.; Puzio-Kuter, A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330, 1340-1344.
72. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177-185.
73. Bluemlein, K.; Gruning, N.M.; Feichtinger, R.G.; Lehrach, H.; Kofler, B.; Ralser, M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011, 2, 393-400.
74. Christofk, H.R.; Vander Heiden, M.G.; Harris, M.H.; Ramanathan, A.; Gerszten, R.E.; Wei, R.; Fleming, M.D.; Schreiber, S.L.; Cantley, L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452, 230-233.
75. Maddocks, O.D.; Vousden, K.H. Metabolic regulation by p53. J. Mol. Med. (Berl.) 2011, 89, 237-245.
76. Sinha, S.; Ghildiyal, R.; Mehta, V.S.; Sen, E. ATM-NFkappab axis-driven tigar regulates sensitivity of glioma cells to radiomimetics in the presence of TNFalpha. Cell Death Dis. 2013, 4, e615.
77. Molinari, F.; Frattini, M. Functions and regulation of the PTEN gene in colorectal cancer. Front. Oncol. 2013, 3, e326.
78. Chalhoub, N.; Baker, S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4, 127-150.
79. Elstrom, R.L.; Bauer, D.E.; Buzzai, M.; Karnauskas, R.; Harris, M.H.; Plas, D.R.; Zhuang, H.; Cinalli, R.M.; Alavi, A.; Rudin, C.M. et al. AKT stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64, 3892-3899.
80. Buzzai, M.; Bauer, D.E.; Jones, R.G.; Deberardinis, R.J.; Hatzivassiliou, G.; Elstrom, R.L.; Thompson, C.B. The glucose dependence of AKT-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005, 24, 4165-4173.
81. Ogino, S.; Kawasaki, T.; Ogawa, A.; Kirkner, G.J.; Loda, M.; Fuchs, C.S. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum. Pathol. 2007, 38, 614-620.
82. Fleming, N.I.; Jorissen, R.N.; Mouradov, D.; Christie, M.; Sakthianandeswaren, A.; Palmieri, M.; Day, F.; Li, S.; Tsui, C.; Lipton, L. et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013, 73, 725-735.
83. Bellam, N.; Pasche, B. TGF-beta signaling alterations and colon cancer. Cancer Treat. Res. 2010, 155, 85-103.
84. Kim, Y.S.; Yi, Y.; Choi, S.G.; Kim, S.J. Development of TGF-beta resistance during malignant progression. Arch. Pharm. Res. 1999, 22, 1-8.
85. Chan, E.C.; Koh, P.K.; Mal, M.; Cheah, P.Y.; Eu, K.W.; Backshall, A.; Cavill, R.; Nicholson, J.K.; Keun, H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 2009, 8, 352-361.
86. Denkert, C.; Budczies, J.; Weichert, W.; Wohlgemuth, G.; Scholz, M.; Kind, T.; Niesporek, S.; Noske, A.; Buckendahl, A.; Dietel, M. et al. Metabolite profiling of human colon carcinoma-Deregulation of TCA cycle and amino acid turnover. Mol. Cancer 2008, 7, doi:10.1186/1476-4598-7-72.
87. Tessem, M.B.; Selnaes, K.M.; Sjursen, W.; Trano, G.; Giskeodegard, G.F.; Bathen, T.F.; Gribbestad, I.S.; Hofsli, E. Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J. Proteome Res. 2010, 9, 3664-3670.
88. Monleon, D.; Morales, J.M.; Barrasa, A.; Lopez, J.A.; Vazquez, C.; Celda, B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009, 22, 342-348.
89. Weir, T.L.; Manter, D.K.; Sheflin, A.M.; Barnett, B.A.; Heuberger, A.L.; Ryan, E.P. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 2013, 8, e70803.
90. Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Zheng, X.; Xu, Y.; Ni, Y.; Zhao, A.; Xu, L.X.; Cai, S. et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J. Proteome Res. 2009, 8, 4844-4850.
91. Kondo, Y.; Nishiumi, S.; Shinohara, M.; Hatano, N.; Ikeda, A.; Yoshie, T.; Kobayashi, T.; Shiomi, Y.; Irino, Y.; Takenawa, T. et al. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomark. Med. 2011, 5, 451-460.
92. Ludwig, C.; Ward, D.G.; Martin, A.; Viant, M.R.; Ismail, T.; Johnson, P.J.; Wakelam, M.J.; Gunther, U.L. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn. Reson. Chem. 2009, 47, S68-S73.
93. Leichtle, A.B.; Nuoffer, J.M.; Ceglarek, U.; Kase, J.; Conrad, T.; Witzigmann, H.; Thiery, J.; Fiedler, G.M. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012, 8, 643-653.
94. Nishiumi, S.; Kobayashi, T.; Ikeda, A.; Yoshie, T.; Kibi, M.; Izumi, Y.; Okuno, T.; Hayashi, N.; Kawano, S.; Takenawa, T. et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 2012, 7, e40459.
95. Farshidfar, F.; Weljie, A.M.; Kopciuk, K.; Buie, W.D.; Maclean, A.; Dixon, E.; Sutherland, F.R.; Molckovsky, A.; Vogel, H.J.; Bathe, O.F. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med. 2012, 4, doi:10.1186/gm341.
96. Tan, B.; Qiu, Y.; Zou, X.; Chen, T.; Xie, G.; Cheng, Y.; Dong, T.; Zhao, L.; Feng, B.; Hu, X. et al. Metabonomics identifies serum metabolite markers of colorectal cancer. J. Proteome Res. 2013, 12, 3000-3009.
97. Bertini, I.; Cacciatore, S.; Jensen, B.V.; Schou, J.V.; Johansen, J.S.; Kruhoffer, M.; Luchinat, C.; Nielsen, D.L.; Turano, P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012, 72, 356-364.
98. Xia, J.; Psychogios, N.; Young, N.; Wishart, D.S. Metaboanalyst: A web server for metabolomic data analysis and interpretation. Nucl. Acids Res. 2009, 37, W652-W660.
99. Ingenuity Systems Pathway Analysis. Availbale online: http://www.ingenuity.com/ (aceessed on 23 December 2014).
100. Li, C.; Han, J.; Yao, Q.; Zou, C.; Xu, Y.; Zhang, C.; Shang, D.; Zhou, L.; Zou, C.; Sun, Z. et al. Subpathway-GM: Identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways. Nucl. Acids Res. 2013, 41, e101.
101. Nibbe, R.K.; Koyutürk, M.; Chance, M.R. An integrative-omics approach to identify functional sub-networks in human colorectal cancer. PLoS Comput. Biol. 2010, 6, e1000639.
102. Kanani, H.; Dutta, B.; Klapa, M.I. Individual vs. Combinatorial effect of elevated CO2 conditions and salinity stress on arabidopsis thaliana liquid cultures: Comparing the early molecular response using time-series transcriptomic and metabolomic analyses. BMC Syst. Biol. 2010, 4, doi:10.1186/1752-0509-4-177.
103. Grimplet, J.; Cramer, G.R.; Dickerson, J.A.; Mathiason, K.; van Hemert, J.; Fennell, A.Y. Vitisnet: "Omics" integration through grapevine molecular networks. PLoS One 2009, 4, e8365.
104. Oberbach, A.; Bluher, M.; Wirth, H.; Till, H.; Kovacs, P.; Kullnick, Y.; Schlichting, N.; Tomm, J.M.; Rolle-Kampczyk, U.; Murugaiyan, J. et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J. Proteome Res. 2011, 10, 4769-4788.
105. Wong, C.K.; Vaske, C.J.; Ng, S.; Sanborn, J.Z.; Benz, S.C.; Haussler, D.; Stuart, J.M. The UCSC interaction browser: Multidimensional data views in pathway context. Nucl. Acids Res. 2013, 41, W218-W224.
106. Cbioportal for cancer genomics. Avaible online: http://www.cbioportal.org/public-portal/ (accessed on 14 January 2014).
107. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E. et al. The cbio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401-404.
108. Interaction browser. Avaible online: http://sysbio.soe.ucsc.edu/nets/ (accessed on 14 January 2014).
109. Qiu, Y.; Cai, G.; Zhou, B.D.O.M.; Li, D.; Zhao, A.; Xie, G.; Li, H.; Cai, S.; Xie, D.; Huang, C. et al. A distinct metabolic signature of human colorectal cancer with prognostic potential. Clin. Cancer Res. 2014, 20, 2136-2146.
110. Manna, S.K.; Tanaka, N.; Krausz, K.W.; Haznadar, M.; Xue, X.; Matsubara, T.; Bowman, E.D.; Fearon, E.R.; Harris, C.C.; Shah, Y.M. et al. Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans. Gastroenterology 2014, 146, 1313-1324.
111. Douillard, J.Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013, 369, 1023-1034.
112. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O'Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359, 1757-1765.
113. Leanza, L.; Zoratti, M.; Gulbins, E.; Szabo, I. Mitochondrial ion channels as oncological targets. Oncogene 2014, doi:10.1038/onc.2013.578.
114. Evans, J.M.; Donnelly, L.A.; Emslie-Smith, A.M.; Alessi, D.R.; Morris, A.D. Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 2005, 330, 1304-1305.
115. Bowker, S.L.; Majumdar, S.R.; Veugelers, P.; Johnson, J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29, 254-258.
116. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69, 7507-7511.
117. Jiralerspong, S.; Palla, S.L.; Giordano, S.H.; Meric-Bernstam, F.; Liedtke, C.; Barnett, C.M.; Hsu, L.; Hung, M.C.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 2009, 27, 3297-3302.
118. Higurashi, T.; Takahashi, H.; Endo, H.; Hosono, K.; Yamada, E.; Ohkubo, H.; Sakai, E.; Uchiyama, T.; Hata, Y.; Fujisawa, N. et al. Metformin efficacy and safety for colorectal polyps: A double-blind randomized controlled trial. BMC Cancer 2012, 12, doi:10.1186/1471-2407-12-118.
119. Jardim, D.L.; Wheler, J.J.; Hess, K.; Tsimberidou, A.M.; Zinner, R.; Janku, F.; Subbiah, V.; Naing, A.; Piha-Paul, S.A.; Westin, S.N. et al. FBXW7 mutations in patients with advanced cancers: Clinical and molecular characteristics and outcomes with mtor inhibitors. PLoS One 2014, 9, e89388.
120. Francipane, M.G.; Lagasse, E. mTOR Pathway in colorectal cancer: An update. Oncotarget 2014, 5, 49-66.
121. Francipane, M.G.; Lagasse, E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget 2013, 4, 1948-1962.
122. Ewing, G.P.; Goff, L.W. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin. Colorectal Cancer 2010, 9, 219-223.
123. Golan, T.; Javle, M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park) 2011, 25, 518-526, 529.
124. Gaglio, D.; Soldati, C.; Vanoni, M.; Alberghina, L.; Chiaradonna, F. Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in K-ras transformed fibroblasts. PLoS One 2009, 4, e4715.
125. Clem, B.; Telang, S.; Clem, A.; Yalcin, A.; Meier, J.; Simmons, A.; Rasku, M.A.; Arumugam, S.; Dean, W.L.; Eaton, J. et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 2008, 7, 110-120.